WallStreetZenWallStreetZen

NASDAQ: FATE
Fate Therapeutics Inc Stock

$3.76+0.17 (+4.74%)
Updated Jun 21, 2024
FATE Price
$3.76
Fair Value Price
N/A
Market Cap
$428.01M
52 Week Low
$1.63
52 Week High
$8.83
P/E
-1.96x
P/B
1x
P/S
114.56x
PEG
N/A
Dividend Yield
N/A
Revenue
$6.48M
Earnings
-$190.05M
Gross Margin
100%
Operating Margin
-2,933.79%
Profit Margin
-2,933.8%
Debt to Equity
0.34
Operating Cash Flow
-$137M
Beta
1.62
Next Earnings
Aug 6, 2024
Ex-Dividend
N/A
Next Dividend
N/A

FATE Overview

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how FATE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

FATE is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
FATE is good value based on its book value relative to its share price (1x), compared to the US Biotechnology industry average (6.2x)
P/B vs Industry Valuation
FATE is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more FATE due diligence checks available for Premium users.

Be the first to know about important FATE news, forecast changes, insider trades & much more!

FATE News

Valuation

FATE price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-1.96x
Industry
-5.75x
Market
30.75x

FATE price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1x
Industry
6.2x
FATE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

FATE's financial health

Profit margin

Revenue
$1.9M
Net Income
-$48.0M
Profit Margin
-2,493.7%
FATE's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
FATE's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$569.9M
Liabilities
$143.8M
Debt to equity
0.34
FATE's short-term assets ($394.38M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
FATE's short-term assets ($394.38M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
FATE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
FATE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$33.4M
Investing
$17.3M
Financing
$95.5M
FATE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

FATE vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
FATE$428.01M+4.74%-1.96x1.00x
OCS$429.86M0.00%-7.05x4.95x
TBPH$425.54M+1.04%-9.94x2.08x
IGMS$430.87M+12.14%-1.71x2.67x
ALLO$435.68M+4.51%-1.40x0.94x

Fate Therapeutics Stock FAQ

What is Fate Therapeutics's quote symbol?

(NASDAQ: FATE) Fate Therapeutics trades on the NASDAQ under the ticker symbol FATE. Fate Therapeutics stock quotes can also be displayed as NASDAQ: FATE.

If you're new to stock investing, here's how to buy Fate Therapeutics stock.

What is the 52 week high and low for Fate Therapeutics (NASDAQ: FATE)?

(NASDAQ: FATE) Fate Therapeutics's 52-week high was $8.83, and its 52-week low was $1.63. It is currently -57.42% from its 52-week high and 130.67% from its 52-week low.

How much is Fate Therapeutics stock worth today?

(NASDAQ: FATE) Fate Therapeutics currently has 113,831,969 outstanding shares. With Fate Therapeutics stock trading at $3.76 per share, the total value of Fate Therapeutics stock (market capitalization) is $428.01M.

Fate Therapeutics stock was originally listed at a price of $6.62 in Oct 1, 2013. If you had invested in Fate Therapeutics stock at $6.62, your return over the last 10 years would have been -43.2%, for an annualized return of -5.5% (not including any dividends or dividend reinvestments).

How much is Fate Therapeutics's stock price per share?

(NASDAQ: FATE) Fate Therapeutics stock price per share is $3.76 today (as of Jun 21, 2024).

What is Fate Therapeutics's Market Cap?

(NASDAQ: FATE) Fate Therapeutics's market cap is $428.01M, as of Jun 24, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Fate Therapeutics's market cap is calculated by multiplying FATE's current stock price of $3.76 by FATE's total outstanding shares of 113,831,969.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.